25.61
0.01 (0.04%)
| 前收盘价格 | 25.60 |
| 收盘价格 | 25.58 |
| 成交量 | 410,478 |
| 平均成交量 (3个月) | 527,937 |
| 市值 | 1,007,700,352 |
| 市盈率 (P/E TTM) | 197.00 |
| 预期市盈率 (P/E Forward) | 8.83 |
| 价格/销量 (P/S) | 1.54 |
| 股市价格/股市净资产 (P/B) | 1.56 |
| 52周波幅 |
| 营业毛利率 | -14.76% |
| 营业利益率 (TTM) | 4.63% |
| 稀释每股收益 (EPS TTM) | -2.24 |
| 季度收入增长率 (YOY) | 1.10% |
| 季度盈利增长率 (YOY) | -46.40% |
| 总债务/股东权益 (D/E MRQ) | 79.70% |
| 流动比率 (MRQ) | 2.41 |
| 营业现金流 (OCF TTM) | 175.75 M |
| 杠杆自由现金流 (LFCF TTM) | 144.75 M |
| 资产报酬率 (ROA TTM) | 3.56% |
| 股东权益报酬率 (ROE TTM) | -12.27% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 看涨 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | Pacira BioSciences, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.67 |
|
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 1.79% |
| 机构持股比例 | 110.89% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合